Stock-Based Compensation (Details) - USD ($) $ / shares in Units, $ in Thousands | 3 Months Ended |
Mar. 31, 2019 | Mar. 31, 2018 |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | | |
Total Operating Expenses | | $ 3,182,112 | | $ 2,806,574 |
Stock-Based Compensation Expenses | | $ 39,087 | | 35,486 |
Common Shares Available for Grant | | 12,900,000 | | |
Weighted average period over which unrecognized compensation expense will be recognized (in years) | | 1 year 10 months 24 days | | |
Stock Options and SARs | | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | | |
Stock-based compensation expense related to stock options, SAR and ESPP grants | | $ 13,900 | | $ 12,000 |
Unrecognized compensation expense | [1] | $ 94,600 | | |
Weighted Average Fair Values And Valuation Assumptions Used To Value Stock Option/SARs, ESPP, and Performance Units/Stock Stock-Based Compensation [Abstract] | | | | |
Weighted Average Fair Value of Grants (price per share) | | $ 27.19 | | $ 28.19 |
Expected Volatility (in hundredths) | | 31.81% | | 29.01% |
Risk-Free Interest Rate (in hundredths) | | 2.51% | | 2.09% |
Dividend Yield (in hundredths) | | 0.88% | | 0.66% |
Expected Life (in years) | | 5 years | | 5 years |
Stock Options and SARs Rollforward [Abstract] | | | | |
Outstanding at January 1 (in shares) | | 8,310,000 | | 9,103,000 |
Granted (in shares) | | 17,000 | | 16,000 |
Exercised (1) (in shares) | [1] | (43,000) | | (752,000) |
Forfeited (in shares) | | (48,000) | | (77,000) |
Outstanding at March 31 (2) (in shares) | [2] | 8,236,000 | | 8,290,000 |
Stock Options and SARs Vested or Expected to Vest (3) (in shares) | [3] | 7,892,000 | | 7,940,000 |
Stock Options and SARs Exercisable at March 31 (4) (in shares) | [4] | 3,997,000 | | 3,803,000 |
Intrinsic Value of Stock Options/SARs Exercised | [1] | $ 1,100 | | $ 28,400 |
Weighted Average Remaining Contractual Life for Stock Options/SARs Outstanding (in years) | | 4 years 2 months 12 days | | 4 years 3 months 18 days |
Intrinsic Value of Stock Options/SARs Vested or Expected to Vest | [1] | $ 51,100 | | $ 166,100 |
Weighted average remaining contractual life for stock options/SARs vested or expected to vest (in years) | | 4 years 1 month 6 days | | 4 years 2 months 12 days |
Aggregate Intrinsic Value for Exercisable Units | [1] | $ 43,100 | | $ 110,800 |
Weighted average remaining contractual life for exercisable options/SARs (in years) | | 2 years 8 months 12 days | | 2 years 7 months 6 days |
Weighted Average Grant Price Stock Option and SARs [Rollforward] | | | | |
Intrinsic Value of Stock Options/SARs Outstanding | [1] | $ 51,800 | | $ 170,700 |
Outstanding at January 1 (price per share) | | $ 96.90 | | $ 83.89 |
Granted (price per share) | | 96.67 | | 106.76 |
Exercised (1) (price per share) | [1] | 69.94 | | 74.65 |
Forfeited (price per share) | | 105.43 | | 91.94 |
Outstanding at March 31 (2) (price per share) | [2] | 96.99 | | 84.70 |
Vested or Expected to Vest (3) (price per share) | [3] | 96.53 | | 84.38 |
Exercisable at March 31 (4) (price per share) | [4] | 86.25 | | 76.16 |
ESPP | | | | |
Weighted Average Fair Values And Valuation Assumptions Used To Value Stock Option/SARs, ESPP, and Performance Units/Stock Stock-Based Compensation [Abstract] | | | | |
Weighted Average Fair Value of Grants (price per share) | | $ 22.98 | | $ 23.27 |
Expected Volatility (in hundredths) | | 36.31% | | 22.04% |
Risk-Free Interest Rate (in hundredths) | | 2.48% | | 1.60% |
Dividend Yield (in hundredths) | | 0.83% | | 0.66% |
Expected Life (in years) | | 6 months | | 6 months |
Restricted Stock And Restricted Stock Units | | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | | |
Unrecognized compensation expense | [1] | $ 182,800 | | |
Weighted average period over which unrecognized compensation expense will be recognized (in years) | | 1 year 10 months 24 days | | |
Intrinsic value released during the year | [1] | $ 22,000 | | $ 28,400 |
Aggregate intrinsic value of stock and units outstanding | [1] | 370,200 | | 403,500 |
Restricted Stock/Restricted Stock Units [Roll Forward] | | | | |
Share-Based Compensation Arrangement By Restricted Stock And Restricted Stock Units Compensation Cost | [1] | $ 23,300 | | $ 22,400 |
Outstanding at January 1 (in shares) | | 3,792,000 | | 3,905,000 |
Granted (in shares) | | 371,000 | | 279,000 |
Released (1) (in shares) | [5] | (247,000) | | (276,000) |
Forfeited (in shares) | | (26,000) | | (75,000) |
Outstanding at March 31 (2) (in shares) | [6] | 3,890,000 | | 3,833,000 |
Weighted Average Grant Price Restricted Stock and Restricted Stock Units [Roll Forward] | | | | |
Outstanding at January 1 (price per share) | | $ 96.64 | | $ 88.57 |
Granted (price per share) | | 96.72 | | 102.27 |
Released (1) (price per share) | [5] | 93.37 | | 66.46 |
Forfeited (price per share) | | 98.11 | | 90.65 |
Outstanding at September 30 (2) (price per share) | [6] | $ 96.85 | | $ 91.12 |
Performance Unit | | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | | |
Stock-Based Compensation Expenses | [1] | $ 1,900 | | $ 1,100 |
Unrecognized compensation expense | | $ 7,900 | | |
Weighted average period over which unrecognized compensation expense will be recognized (in years) | | 1 year 7 months 6 days | | |
Aggregate intrinsic value of stock and units outstanding | | $ 58,100 | | $ 60,400 |
Minimum Performance Units and Stock Allowed to be Outstanding | | 287 | | |
Maximum Performance Units and Stock Allowed to be Outstanding | | 934 | | |
Restricted Stock/Restricted Stock Units [Roll Forward] | | | | |
Outstanding at January 1 (in shares) | | 539 | | 502 |
Granted (in shares) | | 0 | | 0 |
Granted for Performance Multiple (1) | [7] | 72 | | 72 |
Released (1) (in shares) | | 0 | | 0 |
Forfeited (in shares) | | 0 | | 0 |
Outstanding at March 31 (2) (in shares) | [8] | 611 | [9] | 574 |
Weighted Average Grant Price Restricted Stock and Restricted Stock Units [Roll Forward] | | | | |
Outstanding at January 1 (price per share) | | $ 101.53 | | $ 90.96 |
Granted (price per share) | | 0 | | 0 |
Granted for Performance Multiple (1) (in dollars per share) | [7] | 69.43 | | 101.87 |
Released (1) (price per share) | | 0 | | 0 |
Forfeited (price per share) | | 0 | | 0 |
Outstanding at September 30 (2) (price per share) | [8] | $ 97.75 | | $ 92.33 |
Performance Units and Performance Stock Disclosures [Abstract] | | | | |
Performance Period for Performance Units and Shares | | 3 years | | |
Minimum Performance Multiple at the Completion of the Performance Period | | 0.00% | | |
Maximum Performance Multiple at the Completion of the Performance Period | | 200.00% | | |
Lease and Well | | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | | |
Stock-Based Compensation Expenses | | $ 13,700 | | $ 12,800 |
Gathering and Processing Costs | | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | | |
Stock-Based Compensation Expenses | | 200 | | 100 |
Exploration Costs | | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | | |
Stock-Based Compensation Expenses | | 6,500 | | 6,900 |
General and Administrative | | | | |
Stock Options/SARs and Employee Stock Purchase Plan (ESPP) Disclosures [Line Items] | | | | |
Stock-Based Compensation Expenses | | $ 18,700 | | $ 15,700 |
| |
[1] | The total intrinsic value of stock options/SARs exercised for the three months ended March 31, 2019 and 2018 was $1.1 million and $28.4 million, respectively. The intrinsic value is based upon the difference between the market price of EOG's common stock on the date of exercise and the grant price of the stock options/SARs. | |
[2] | The total intrinsic value of stock options/SARs outstanding at March 31, 2019 and 2018 was $51.8 million and $170.7 million, respectively. At March 31, 2019 and 2018, the weighted average remaining contractual life was 4.2 years and 4.3 years, respectively. | |
[3] | The total intrinsic value of stock options/SARs vested or expected to vest at March 31, 2019 and 2018 was $51.1 million and $166.1 million, respectively. At March 31, 2019 and 2018, the weighted average remaining contractual life was 4.1 years and 4.2 years, respectively. | |
[4] | The total intrinsic value of stock options/SARs exercisable at March 31, 2019 and 2018 was $43.1 million and $110.8 million, respectively. At March 31, 2019 and 2018, the weighted average remaining contractual life was 2.7 years and 2.6 years, respectively. | |
[5] | The total intrinsic value of restricted stock and restricted stock units released for the three months ended March 31, 2019 and 2018 was $22.0 million and $28.4 million, respectively. The intrinsic value is based upon the closing price of EOG's common stock on the date the restricted stock and restricted stock units are released. | |
[6] | The total intrinsic value of restricted stock and restricted stock units outstanding at March 31, 2019 and 2018 was $370.2 million and $403.5 million, respectively. | |
[7] | Upon completion of the Performance Period for the performance units granted in 2015 and 2014, a performance multiple of 200% was applied to each of the grants resulting in additional grants of performance units in February 2019 and February 2018, respectively. | |
[8] | The total intrinsic value of performance units outstanding at March 31, 2019 and 2018 was approximately $58.1 million and $60.4 million, respectively. | |
[9] | Upon the application of the relevant performance multiple at the completion of each of the remaining Performance Periods, a minimum of 287 and a maximum of 934 performance units could be outstanding. | |